CRSP

SEC source: 0000899243-17-029618 · doc4.xml · nonDerivative · entry 1

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,724

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.20 to $20.56, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-17-029615 · doc4.xml · nonDerivative · entry 1

Woiwode Thomas · CIK 0001619294 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,959

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.20 to $20.42, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-17-029537 · doc4.xml · derivative · entry 2

Kulkarni Samarth · CIK 0001682019 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 279,558

Underlying: Common Shares · 15,000 shares

Expires 2025-09-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vest in equal 36 monthly installments thereafter.

SEC source: 0000899243-17-029537 · doc4.xml · nonDerivative · entry 1

Kulkarni Samarth · CIK 0001682019 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 148,560

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-17-029163 · doc4.xml · nonDerivative · entry 1

Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,204

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.70 to $19.32, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 21

CELGENE CORP /DE/ · CIK 0000816284 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See explanation of responses

Disclosed balance after: 3,722,534

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.

SEC source: 0000899243-17-027954 · doc4.xml · derivative · entry 2

Kulkarni Samarth · CIK 0001682019 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 260,000

Underlying: Common Shares · 260,000 shares

Expires 2027-12-01

F1 · derivative.exercise_date: This option was granted on December 1, 2017 and shall vest in 48 equal monthly installments.

SEC source: 0000899243-17-027954 · doc4.xml · nonDerivative · entry 1

Kulkarni Samarth · CIK 0001682019 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,560

SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 20

CELGENE CORP /DE/ · CIK 0000816284 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See explanation of responses

Disclosed balance after: 3,753,019

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.

SEC source: 0000899243-18-007464 · doc4.xml · derivative · entry 1

Kulkarni Samarth · CIK 0001682019 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Shares · 75,000 shares

Expires 2027-12-01

F1 · derivative.exercise_date: This performance-based option was granted on December 1, 2017 with respect to 75,000 Common Shares, with 75% of the shares vesting on December 1, 2020 and the remaining 25% of the shares vesting on December 1, 2021.

SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 19

CELGENE CORP /DE/ · CIK 0000816284 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See explanation of responses

Disclosed balance after: 3,841,010

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.

SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 18

CELGENE CORP /DE/ · CIK 0000816284 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See explanation of responses

Disclosed balance after: 3,853,676

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.

SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 17

CELGENE CORP /DE/ · CIK 0000816284 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See explanation of responses

Disclosed balance after: 3,857,939

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.

SEC source: 0000899243-17-027487 · doc4.xml · nonDerivative · entry 2

Woiwode Thomas · CIK 0001619294 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,018

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0000899243-17-027486 · doc4.xml · nonDerivative · entry 2

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,740

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 16

CELGENE CORP /DE/ · CIK 0000816284 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See explanation of responses

Disclosed balance after: 3,863,019

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.

SEC source: 0000899243-17-027487 · doc4.xml · nonDerivative · entry 1

Woiwode Thomas · CIK 0001619294 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,218

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.20 to $20.25, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-17-027486 · doc4.xml · nonDerivative · entry 1

Bolzon Bradley J PhD · CIK 0001354345 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,940

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.20 to $20.25, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 15

CELGENE CORP /DE/ · CIK 0000816284 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See explanation of responses

Disclosed balance after: 3,891,009

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.

SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 14

CELGENE CORP /DE/ · CIK 0000816284 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See explanation of responses

Disclosed balance after: 3,917,019

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.

SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 12

CELGENE CORP /DE/ · CIK 0000816284 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See explanation of responses

Disclosed balance after: 4,253,019

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.

SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 11

CELGENE CORP /DE/ · CIK 0000816284 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See explanation of responses

Disclosed balance after: 4,411,737

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.

SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 10

CELGENE CORP /DE/ · CIK 0000816284 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See explanation of responses

Disclosed balance after: 4,463,019

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.

SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 9

CELGENE CORP /DE/ · CIK 0000816284 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See explanation of responses

Disclosed balance after: 4,568,019

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4

F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.

SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 8

CELGENE CORP /DE/ · CIK 0000816284 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See explanation of responses

Disclosed balance after: 4,583,019

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4

F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.

SEC source: 0000899243-17-026210 · doc4.xml · derivative · entry 1

TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Shares · 180,000 shares

Expires 2027-11-21

F1 · derivative.exercise_date: This option was granted on November 13, 2017, 25% of the shares shall vest on November 13, 2018 and the remaining shares shall vest in 36 equal monthly installments on the first day of each succeeding calendar month.

SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 7

CELGENE CORP /DE/ · CIK 0000816284 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See explanation of responses

Disclosed balance after: 4,597,926

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4

F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.

SEC source: 0001209191-20-045100 · doc4.xml · derivative · entry 4

TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 168,000

Underlying: Common Shares · 12,000 shares

Expires 2027-11-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: This option was granted on November 13, 2017, 25% of the shares vested on November 13, 2018 and the remaining shares vest in 36 equal monthly installments on the first day of each succeeding calendar month.

SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 6

CELGENE CORP /DE/ · CIK 0000816284 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See explanation of responses

Disclosed balance after: 4,663,019

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4

F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.

SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 5

CELGENE CORP /DE/ · CIK 0000816284 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See explanation of responses

Disclosed balance after: 4,673,019

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4

F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.

SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 4

CELGENE CORP /DE/ · CIK 0000816284 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See explanation of responses

Disclosed balance after: 4,693,019

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4

F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.

SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 3

CELGENE CORP /DE/ · CIK 0000816284 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See explanation of responses

Disclosed balance after: 4,709,894

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4

F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.

SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 2

CELGENE CORP /DE/ · CIK 0000816284 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See explanation of responses

Disclosed balance after: 4,732,894

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4

F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.

SEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 1

CELGENE CORP /DE/ · CIK 0000816284 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See explanation of responses

Disclosed balance after: 4,812,221

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4

F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.

F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.

SEC source: 0000899243-17-021477 · doc4.xml · derivative · entry 4

Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,826

Underlying: Common Shares · 3,853 shares

Expires 2025-09-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 shares immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter.

SEC source: 0000899243-17-021477 · doc4.xml · nonDerivative · entry 3

Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,148,007

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.60, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-17-021477 · doc4.xml · nonDerivative · entry 2

Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,151,860

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-17-051986 · doc4.xml · nonDerivative · entry 12

Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner

Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures IV, LLC · CIK 0001456589 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · see footnote

Disclosed balance after: 0

F21 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V CAN without consideration to its partners.

F20 · ownership.nature: The shares are held VV V CAN.

SEC source: 0001209191-17-051986 · doc4.xml · nonDerivative · entry 11

Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner

Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures IV, LLC · CIK 0001456589 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · see footnote

Disclosed balance after: 1,240

F19 · kind: Represents a change in the form of ownership of VV V CAN by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC CAN.

F20 · ownership.nature: The shares are held VV V CAN.

SEC source: 0001209191-17-051986 · doc4.xml · nonDerivative · entry 10

Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner

Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures IV, LLC · CIK 0001456589 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · see footnote

Disclosed balance after: 0

F18 · kind: . Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V without consideration to its members.

F17 · ownership.nature: The shares are held VV V.

SEC source: 0001209191-17-051986 · doc4.xml · nonDerivative · entry 9

Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner

Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures IV, LLC · CIK 0001456589 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · see footnote

Disclosed balance after: 17,283

F16 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC V, VAF V and VOA.

F17 · ownership.nature: The shares are held VV V.

SEC source: 0001209191-17-051986 · doc4.xml · nonDerivative · entry 8

Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner

Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures IV, LLC · CIK 0001456589 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · see footnote

Disclosed balance after: 0

F15 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV IV without consideration to its members.

F14 · ownership.nature: The shares are held VV IV.

SEC source: 0001209191-17-051986 · doc4.xml · nonDerivative · entry 7

Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner

Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures IV, LLC · CIK 0001456589 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · see footnote

Disclosed balance after: 292,529

F13 · kind: Represents a change in the form of ownership of VV IV by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC IV and VSF IV.

F14 · ownership.nature: The shares are held VV IV.

SEC source: 0001209191-17-051986 · doc4.xml · nonDerivative · entry 6

Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner

Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures IV, LLC · CIK 0001456589 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · see footnote

Disclosed balance after: 52,987

F11 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA") without consideration to its partners.

F12 · ownership.nature: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VOA, except to the extent of its pecuniary interest therein.

SEC source: 0001209191-17-051986 · doc4.xml · nonDerivative · entry 5

Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner

Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures IV, LLC · CIK 0001456589 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · see footnote

Disclosed balance after: 123,994

F9 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital V (Canada) LP ("VVC CAN") without consideration to its partners.

F10 · ownership.nature: These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities, however, each disclaim beneficial ownership of the securities held by VVC CAN, except to the extent of their respective pecuniary interests therein.

SEC source: 0001209191-17-051986 · doc4.xml · nonDerivative · entry 4

Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner

Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures IV, LLC · CIK 0001456589 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · see footnote

Disclosed balance after: 47,801

F7 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Affiliates Fund V, L.P. ("VAF V") without consideration to its partners.

F8 · ownership.nature: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VAF V, except to the extent of its pecuniary interest therein.

SEC source: 0001209191-17-051986 · doc4.xml · nonDerivative · entry 3

Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner

Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures IV, LLC · CIK 0001456589 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · see footnote

Disclosed balance after: 1,629,204

F5 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital V, L.P. ("VVC V") without consideration to its partners.

F6 · ownership.nature: These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities, however, VV V disclaims beneficial ownership of the securities held by VVC V, except to the extent of its pecuniary interest therein.

SEC source: 0001209191-17-051986 · doc4.xml · nonDerivative · entry 2

Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner

Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures IV, LLC · CIK 0001456589 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · see footnote

Disclosed balance after: 16,224

F3 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Side Fund IV, L.P. ("VSF IV") without consideration to its partners.

F4 · ownership.nature: These securities are held of record by VSF IV. VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VSF IV, except to the extent of its pecuniary interest therein.

SEC source: 0001209191-17-051986 · doc4.xml · nonDerivative · entry 1

Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner

Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner

Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner

Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner

Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner

Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner

Versant Ventures IV, LLC · CIK 0001456589 · 10% owner

Versant Ventures V, LLC · CIK 0001619298 · 10% owner

Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · see footnote

Disclosed balance after: 2,736,032

F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("VVC IV") without consideration to its partners.

F2 · ownership.nature: These securities are held of record by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities, however, VV IV disclaims beneficial ownership of the securities held by VVC IV, except to the extent of its pecuniary interest therein.

SEC source: 0001209191-17-051985 · doc4.xml · nonDerivative · entry 13

Woiwode Thomas · CIK 0001619294 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,918

F22 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VV IV, VV V and VV V CAN to their members or partners.